Skip to main content

REPLACE: (Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy): A Look at Phase IV Study Data

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Vijay Balasubramanian M.D.

    Clinical Professor of Medicine
    Medical Director of Pulmonary Hypertension Program
    Medical Director, Pulmonary Function Laboratory Services UCSF Fresno
    Chair, Pulmonary Vascular Network, American College of Chest Physicians.

May 9, 2022
Mon 12:00 PM EDT

Duration 1H 0M

This live web event has ended.

For Technical Support
(888) 705-6002
+1 (858) 201-4136*
*for callers residing outside of the United States